Women with HER2+ early breast cancer who achieved pathologic complete response (pCR) on neoadjuvant treatment had improved overall survival (OS) and event-free survival (EFS) outcomes, according to final analysis results of the phase III NeoALTTO, BIG 1-06 trial.
The use of an algorithm to identify the presence of coronary artery calcifications (CAC) during radiotherapy-planning CT scans may help assess cardiovascular disease (CVD) risk in women with breast cancer, according to a study from the Netherlands.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.